Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2024-07-15 Regulatory Filings
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short notice informing about an upcoming Board Meeting scheduled for 26th July 2024 to consider and approve the unaudited financial results for the quarter ended 30th June 2024. It also mentions the closure of the trading window for securities dealing. The document does not contain any actual financial data or detailed financial statements, nor does it include the results themselves. It is an announcement of a future event related to financial results, not the results or report itself. The document length is only 1713 characters, which is quite short and consistent with an announcement rather than a full report. Therefore, according to the rules, this is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement about the board meeting and financial results approval date, not the financial report itself or a detailed earnings release.
2024-07-15 English
Board Meeting — PIRAMAL PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 26-Jul-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for th…
Regulatory Filings
2024-07-15 English
Board Meeting — PIRAMAL PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 26-Jul-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for th…
Regulatory Filings
2024-07-15 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 70% confidence The document is an announcement dated 15th July 2024 from Piramal Pharma Limited regarding an upcoming conference call with investors and analysts scheduled for 26th July 2024 to discuss the Q1 FY25 financial results. It includes dial-in details and registration information for the call. The document does not contain any financial data, analysis, or the actual earnings results but merely informs about the event where such information will be discussed. This fits the definition of a Call Transcript (CT) only if it contained the full transcript, but here it is only an announcement of the call. It is not an Earnings Release (ER) because it does not provide key financial highlights or results. Given the content and length (3805 characters), it is an announcement of a conference call, which aligns best with the Call Transcript category as the closest relevant category for conference call announcements and transcripts. However, since the document is only an announcement and not a transcript, the best fit is Call Transcript (CT) with moderate confidence, as no other category specifically covers conference call announcements alone.
2024-07-15 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short notice dated 15th July 2024 addressed to stock exchanges, informing about an upcoming Board Meeting scheduled for 26th July 2024 to consider and approve the unaudited financial results for the quarter ended 30th June 2024. It also mentions the closure of the trading window for securities dealing. The document does not contain any financial data or the actual financial results but is an announcement of the meeting where such results will be approved. The length is only 1713 characters, which is quite short and fits the pattern of an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement about the board meeting and financial results approval, not the results themselves or a detailed report.
2024-07-15 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It announces the successful completion of a US FDA Pre-Approval Inspection at a manufacturing facility. The document is brief (1680 characters) and serves as an announcement of an event rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed regulatory filings. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-07-12 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.